PL3618875T3 - Terapia skojarzona obejmująca inhibitor raf i trametynib - Google Patents

Terapia skojarzona obejmująca inhibitor raf i trametynib

Info

Publication number: PL3618875T3
Authority: PL; Poland
Prior art keywords: trametinib; combination therapy; raf inhibitor; raf; inhibitor
Prior art date: 2017-05-02

Application number

PL18726224.1T

Other languages

English (en)

Inventor

Vesselina COOKE

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2017-05-02

Filing date

2018-04-30

Publication date

2023-10-23

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=62218018&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3618875(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2018-04-30 Application filed by Novartis Ag filed Critical Novartis Ag

2023-10-23 Publication of PL3618875T3 publication Critical patent/PL3618875T3/pl

Links

238000002648 combination therapy Methods 0.000 title 1
239000003112 inhibitor Substances 0.000 title 1
LIRYPHYGHXZJBZ-UHFFFAOYSA-N trametinib Chemical compound CC(=O)NC1=CC=CC(N2C(N(C3CC3)C(=O)C3=C(NC=4C(=CC(I)=CC=4)F)N(C)C(=O)C(C)=C32)=O)=C1 LIRYPHYGHXZJBZ-UHFFFAOYSA-N 0.000 title 1
229960004066 trametinib Drugs 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

PL18726224.1T 2017-05-02 2018-04-30 Terapia skojarzona obejmująca inhibitor raf i trametynib PL3618875T3 (pl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201762500108P	2017-05-02	2017-05-02
US201862656423P	2018-04-12	2018-04-12
PCT/IB2018/052989 WO2018203219A1 (en)	2017-05-02	2018-04-30	Combination therapy

Publications (1)

Publication Number	Publication Date
PL3618875T3 true PL3618875T3 (pl)	2023-10-23

Family

ID=62218018

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL18726224.1T PL3618875T3 (pl)	2017-05-02	2018-04-30	Terapia skojarzona obejmująca inhibitor raf i trametynib

Country Status (18)

Country	Link
US (2)	US11266653B2 (pl)
EP (2)	EP4272740A1 (pl)
JP (2)	JP7309614B2 (pl)
KR (2)	KR102641827B1 (pl)
CN (1)	CN110494166B (pl)
AU (1)	AU2018262891B2 (pl)
BR (1)	BR112019022511A2 (pl)
CA (1)	CA3057969A1 (pl)
CL (1)	CL2019003091A1 (pl)
DK (1)	DK3618875T3 (pl)
ES (1)	ES2952265T3 (pl)
FI (1)	FI3618875T3 (pl)
IL (1)	IL270224B1 (pl)
MX (1)	MX2019012884A (pl)
PL (1)	PL3618875T3 (pl)
PT (1)	PT3618875T (pl)
TW (1)	TWI798218B (pl)
WO (1)	WO2018203219A1 (pl)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN111201023A (zh) *	2017-08-11	2020-05-26	启码策有限公司	用于靶向癌症中的多个突变的药物组合物
MX2021007477A (es)	2018-12-20	2021-08-05	Novartis Ag	Terapia de combinacion con un inhibidor de raf y un inhibidor de cdk4/6 para utilizar en el tratamiento del cancer.
EP4106756A1 (en) *	2020-02-18	2022-12-28	Novartis AG	Therapeutic combinations comprising a raf inhibitor for use in treating braf mutant nsclc
WO2021172582A1 (ja) *	2020-02-27	2021-09-02	国立大学法人北海道大学	抗がん剤をスクリーニングする方法及び膵がんの治療のためのキナーゼ阻害剤の組み合わせ医薬
JP2023525100A (ja) *	2020-05-12	2023-06-14	ノバルティスアーゲー	Ｃｒａｆ阻害剤を含む治療的組み合わせ
EP4203963A1 (en) *	2020-08-31	2023-07-05	Novartis AG	Combination therapy of a raf inhibitor and a mek inhibitor for the treatment of sarcoma
WO2023145530A1 (ja) *	2022-01-27	2023-08-03	国立大学法人東北大学	癌治療剤
WO2023166345A2 (en)	2022-03-02	2023-09-07	Novartis Ag	Precision therapy for the treatment of cancer
WO2024054591A1 (en)	2022-09-07	2024-03-14	Arvinas Operations, Inc.	Rapidly accelerated fibrosarcoma (raf) degrading compounds and associated methods of use

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN1219753C (zh)	2000-07-19	2005-09-21	沃尼尔·朗伯公司	4－碘苯氨基苯氧肟酸的氧合酯
PL1761528T3 (pl)	2004-06-11	2008-05-30	Japan Tobacco Inc	Pochodne 5-amino-2,4,7-triokso-3,4,7,8-tetrahydro-2H-pirydo[2,3-D]pirymidyny i związki pokrewne do leczenia raka
TWI505828B (zh)	2010-12-20	2015-11-01	葛蘭素史克智慧財產（第二）有限公司	新穎醫藥組成物
AR091876A1 (es) *	2012-07-26	2015-03-04	Novartis Ag	Combinaciones farmaceuticas para el tratamiento de enfermedades proliferativas
JP2015527374A (ja) *	2012-09-04	2015-09-17	グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅＬＬＣ	アジュバント癌治療の方法
US9242969B2 (en)	2013-03-14	2016-01-26	Novartis Ag	Biaryl amide compounds as kinase inhibitors
CN109715163B (zh)	2016-09-19	2022-11-22	诺华股份有限公司	包含raf抑制剂和erk抑制剂的治疗组合

2018
- 2018-04-30 TW TW107114676A patent/TWI798218B/zh active
- 2018-04-30 EP EP23166366.7A patent/EP4272740A1/en active Pending
- 2018-04-30 WO PCT/IB2018/052989 patent/WO2018203219A1/en unknown
- 2018-04-30 AU AU2018262891A patent/AU2018262891B2/en active Active
- 2018-04-30 US US16/610,482 patent/US11266653B2/en active Active
- 2018-04-30 PT PT187262241T patent/PT3618875T/pt unknown
- 2018-04-30 CA CA3057969A patent/CA3057969A1/en active Pending
- 2018-04-30 BR BR112019022511-0A patent/BR112019022511A2/pt unknown
- 2018-04-30 DK DK18726224.1T patent/DK3618875T3/da active
- 2018-04-30 MX MX2019012884A patent/MX2019012884A/es unknown
- 2018-04-30 KR KR1020197031788A patent/KR102641827B1/ko active IP Right Grant
- 2018-04-30 EP EP18726224.1A patent/EP3618875B1/en active Active
- 2018-04-30 CN CN201880023601.0A patent/CN110494166B/zh active Active
- 2018-04-30 PL PL18726224.1T patent/PL3618875T3/pl unknown
- 2018-04-30 ES ES18726224T patent/ES2952265T3/es active Active
- 2018-04-30 IL IL270224A patent/IL270224B1/en unknown
- 2018-04-30 FI FIEP18726224.1T patent/FI3618875T3/fi active
- 2018-04-30 JP JP2019558725A patent/JP7309614B2/ja active Active
- 2018-04-30 KR KR1020247006274A patent/KR20240032157A/ko active Search and Examination
2019
- 2019-10-28 CL CL2019003091A patent/CL2019003091A1/es unknown
2022
- 2022-01-26 US US17/584,901 patent/US20220143036A1/en active Pending
2023
- 2023-07-05 JP JP2023110949A patent/JP2023145467A/ja active Pending

Also Published As

Publication number	Publication date
ES2952265T3 (es)	2023-10-30
EP4272740A1 (en)	2023-11-08
RU2019134757A3 (pl)	2021-08-17
AU2018262891A1 (en)	2019-10-17
KR102641827B1 (ko)	2024-03-04
RU2019134757A (ru)	2021-06-02
US11266653B2 (en)	2022-03-08
WO2018203219A1 (en)	2018-11-08
DK3618875T3 (da)	2023-07-10
US20220143036A1 (en)	2022-05-12
JP2023145467A (ja)	2023-10-11
CL2019003091A1 (es)	2020-02-07
CA3057969A1 (en)	2018-11-08
AU2018262891B2 (en)	2021-04-01
KR20240032157A (ko)	2024-03-08
TW201842914A (zh)	2018-12-16
PT3618875T (pt)	2023-08-07
BR112019022511A2 (pt)	2020-05-12
JP2020518568A (ja)	2020-06-25
IL270224A (pl)	2019-12-31
IL270224B1 (en)	2024-04-01
CN110494166A (zh)	2019-11-22
US20200246346A1 (en)	2020-08-06
EP3618875B1 (en)	2023-04-05
EP3618875A1 (en)	2020-03-11
CN110494166B (zh)	2022-11-08
KR20190141164A (ko)	2019-12-23
MX2019012884A (es)	2020-01-14
JP7309614B2 (ja)	2023-07-18
FI3618875T3 (fi)	2023-07-04
TWI798218B (zh)	2023-04-11

Publication	Publication Date	Title
PL3618875T3 (pl)	2023-10-23	Terapia skojarzona obejmująca inhibitor raf i trametynib
IL264931B (en)	2021-09-30	Medicinal combinations containing a raf inhibitor and an erk inhibitor
EP3397359A4 (en)	2019-08-21	THERAPY AND BODY TRAINING DEVICE
IL293377B1 (en)	2023-04-01	Variants of hsd17b13 and their uses
IL262378A (en)	2018-11-29	Compositions and methods containing a capsid assembly inhibitor
GB201707153D0 (en)	2017-06-21	Therapy
ZA201606349B (en)	2017-05-31	Radiotherapy board and couch
EP3572400C0 (en)	2023-10-04	EZH2 INHIBITOR AND ITS USE
PT3582838T (pt)	2023-08-21	Inaladores e métodos relacionados
SI3621694T1 (sl)	2023-10-30	Zaviralci lrrc33 in njihove uporabe
LT3532459T (lt)	2023-11-10	Lsd1 inhibitoriai ir jų medicininis panaudojimas
GB201702406D0 (en)	2017-03-29	Inhalers and related methods
GB201708663D0 (en)	2017-07-12	Therapy
IL255530A (en)	2018-01-31	Efflux-pump inhibitors and therapeutic uses thereof
GB201719646D0 (en)	2018-01-10	Therapy
PT3582837T (pt)	2022-03-25	Inaladores
GB201715194D0 (en)	2017-11-01	Compounds and their therapeutic use
IL261505A (en)	2018-10-31	Combined treatment using liv1-adc and a chemotherapeutic agent
HK1247619A1 (zh)	2018-09-28	使用抗 dc 19抗體–藥物共軛物及長春新鹼的聯合治療
IL270011B (en)	2022-03-01	Medicinal compounds and methods
GB201700526D0 (en)	2017-03-01	Therapeutic use
GB201820761D0 (en)	2019-01-30	Defibrillator status indication and activation
GB201711401D0 (en)	2017-08-30	A new exciting and adaptable table game
GB201715430D0 (en)	2017-11-08	Therapy
PL3354163T3 (pl)	2019-12-31	Materac przenośny